Powered by our proprietary RenMice® platforms, Biocytogen provides an off-the-shelf library of 1M+ fully human antibody sequences spanning 1,000+ targets—ready for rapid drug discovery
SEARCH FOR THE RENSUPER BIOLOGICS LIBRARY
Preclinical Candidate Portfolio
Biocytogen's RenMab®, RenLite®, and RenNano® platforms power the generation of fully human monoclonal, bispecific, and hu-VHH antibodies with strong therapeutic potential.
Through these platforms, we offer a diverse and expanding portfolio of preclinical candidate (PCC) molecules to meet the evolving drug development needs of our partners.
Therapeutic Area  | Product Name | Target (s) | Molecular Format | Mono/Combo Therapy | Indication (s) | Development | Partner | Action |
|---|---|---|---|---|---|---|---|---|
| Oncology | BCG008 | SIGLEC15 | mAb | Mono | Solid tumors | Partnered |   | |
| BCG011/DM001 | TACSTD2 × EGFR | BsADC | Mono | Solid tumors | Partnered | | ||
| BCG012/DM002 | ERBB3 × MUC1 | BsADC | Mono | Solid tumors | Partnered | | ||
| YH001 | CTLA4 | mAb | PD-1 | Solid tumors | Partnered ex-China rights available | | ||
| Mono | Solid tumors | Partnered | | |||||
| YH002 | TNFRSF4 | mAb | YH003+YH001 | Intratumoral injection | Partnered | | ||
| YH003 | CD40 | mAb | PD-1+YH001 | Solid tumors | Partnered | | ||
| PD-1+chemo | Pancreatic ductal adenocarcinoma (1L&2L) | Partnered | | |||||
| PD-1+chemo | Mucosal melanoma | Partnered | | |||||
| YH008 | PDCD1 × CD40 | BsAb | Mono | Solid tumors | Partnered | | ||
| YH013/DM005 | EGFR × MET | BsADC | Mono | Solid tumors | Partnered | | ||
| Rare Diseases | BCG009 | IGF1R | mAb | Mono | Rare Disease | Partnered | |
Stay up to date with the latest library updates
What‘s New on RenSuper
- April 12, 2026TARGET_LIBRARY
Target Library Expanded with Metabolic Targets
The preclinical candidate compound (Target) library has been updated with 4257 new metabolic disease candidates, including detailed MOA summaries and ...
- April 9, 2026PCC_LIBRARY
PCC Library Expanded with Metabolic Targets
The preclinical candidate compound (PCC) library has been updated with 68 new metabolic disease candidates, including detailed MOA summaries and early...
- February 16, 2026BINDER_LIBRARY
New Antibody Binder Sequences Added
Over 33 newly validated antibody binder sequences have been added to the RenSuper library, covering oncology and autoimmune targets. Users can now exp...
RenSuper Antibody Design Workstation is a
digitalized and automated platform enabling
multi-format, fully human antibody 
discovery.
Powered by an advanced 
AI model trained on 100M+ fully human
antibody sequences, the RenSuper Workstation reduces antibody design
timelines from years to hours—eliminating the need for repetitive animal
immunization and CRO outsourcing.
_1768399355761.png)
RenSuper supports drag-and-assemble design of flexible antibody formats, including monoclonal, bispecific, multispecific, VHH, and TCR constructs.
Choose from a million-scale library of fully human binder sequences covering 1,000+ targets to build your next antibody therapeutic.
Built-in affinity and functionality analysis ensures the selection of high-confidence designs.
How to Design Antibodies with RenSuper Workstation
Antibody Design
Contact Us
We work closely with leading biotech and pharmaceutical companies around the world to advance cutting-edge drug discovery programs. Share your inquiry here—we'll be in touch soon.
